Hepatitis C virus: Here comes all-oral treatment

@article{Dugum2014HepatitisCV,
  title={Hepatitis C virus: Here comes all-oral treatment},
  author={Mohannad Dugum and Robert O’shea},
  journal={Cleveland Clinic Journal of Medicine},
  year={2014},
  volume={81},
  pages={159 - 172}
}
  • M. Dugum, R. O’shea
  • Published 1 March 2014
  • Medicine, Biology
  • Cleveland Clinic Journal of Medicine
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new directacting antivirals—sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)— opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development. Direct-acting antiviral drugs open the door for an all-oral regimen, potentially eliminating the need for interferon… 

Figures and Tables from this paper

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
An all‐oral, pegylated interferon (pegIFN)‐free and ribavirin (RBV)‐free single‐tablet of ledipasvir (LDV) and sofosbuvir (SOF) is now approved for the treatment of patients infected with hepatitis C
New Oral Direct-Acting Antiviral Agents for Treatment of Chronic Hepatitis-C Infection in Patients with Chronic Kidney Disease Including Dialysis Patients and Kidney Transplant Recipients
TLDR
As in the general population, the prevalence of HCV in CKD Stage 5D patients varies worldwide, ranging from as low as 1% to as high as over 70%, and between 10 to 50% and up to 70% in many parts of the developing world.
Hepatitis C Treatment: What to Expect in 2017
TLDR
A clinical potential review of three new promising direct-acting antiviral agents developed to fulfill significant unmet medical needs of hepatitis C patients, highlighting the significance of a future free from hepatitis C.
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
  • A. Yau, E. Yoshida
  • Biology, Medicine
    Canadian journal of gastroenterology & hepatology
  • 2014
TLDR
The optimal all-oral interferon-free antiviral regimen likely entails a combination of an NS5B nucleotide polymerase inhibitor with either a second-generation NS3/4A protease inhibitor or an NS 5A replication complex inhibitor with or without RBV.
Sustained virological response with intravenous silibinin: individualized IFN‐free therapy via real‐time modelling of HCV kinetics
  • H. Dahari, S. Shteingart, Y. Lurie
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2015
TLDR
This proof of concept case‐study tested whether interferon‐alfa (IFN)‐free treatment with SIL plus ribavirin (RBV) can achieve sustained virological response (SVR), and whether SIL is safe and feasible for prolonged duration of treatment and mathematical modelling of early on‐treatment HCV kinetics can guide duration of therapy.
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
TLDR
Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C, and the most commonly reported adverse events and laboratory abnormalities were consistent with those expected with ribavirin and peginterferon-α.
Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C
TLDR
It is suggested that the VEL/SOF regimen be used as the first line of therapy in patients with HCV genotype 1 in Iran, and it was considered the most cost-effective strategy.
Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection
TLDR
Sofosbuvir was safe and effective in the treatment of hepatitis C virus genotype 1, 2, 3, or 4 infections, however, the lack of persistence of the sustained virologic response beyond the study duration and long-term safety concerns need to be addressed in future studies.
Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection
TLDR
Recently, the US Food and Drug Administration approved a fixed-dose combination of grazoprevir and elbasvir (GE), the new DAAs, for the treatment of HCV infection caused by genotype (GT) 1 or 4 viruses, with or without ribavirin (R).
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
TLDR
The use of SOF + PR regimen or LDV/SOF can significantly reduce the incidence of complications associated with the disease and short and long-term outcomes are better than the current drug regimens for HCV genotype 1 patients in all stages of the disease.
...
...

References

SHOWING 1-10 OF 58 REFERENCES
Interferon free therapy with direct acting antivirals for HCV
  • T. Asselah, P. Marcellin
  • Biology, Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2013
TLDR
Combinations of antivirals with additive potency that lack cross‐resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.
HCV treatment--no more room for interferonologists?
  • J. Drenth
  • Biology, Medicine
    The New England journal of medicine
  • 2013
TLDR
The increased understanding of the basic biology of HCV led to the identification of specific proteins involved in the replication of the virus, which can be targeted by protease and polymerase inhibitors.
NS5A inhibitors in the treatment of hepatitis C.
The hepatitis C virus life cycle as a target for new antiviral therapies.
TLDR
This article has attempted to highlight important new information as it relates to the understanding of the HCV life cycle, which broadly encompass viral attachment, entry, and fusion; viral RNA translation; posttranslational processing; HCV replication; and viral assembly and release.
Hepatitis C therapy with HCV NS5B polymerase inhibitors
TLDR
Amongst HCV polymerase inhibitors, sofosbuvir has positioned as unique companion with ribavirin as therapy for most HCV genotypes 2 or 3, and along with NS5A inhibitors for other HCV Genotypes.
New horizons in hepatitis C antiviral therapy with direct‐acting antivirals
TLDR
Future research will need to define well‐tolerated and cost‐effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.
Treatment failure with new hepatitis C drugs
TLDR
New antivirals for hepatitis C and HCV treatment failures, along with HCV drug resistance and rescue therapies are reviewed, and the application of early stopping rules may reduce the enrichment of drug-resistant viruses in patients failing first-generation HCV protease inhibitors.
Emerging treatments for hepatitis C
TLDR
There is a need for more effective antiviral therapy for difficult to treat patients who are interferon intolerant, developed liver cirrhosis or non-responders to previous therapies and IFN-free regimens are step for future therapies consisting of combinations of novel investigational DAA and host targeting agents.
The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C
TLDR
The clinical application and mechanism of action of ribavirin, an antiviral agent used in the treatment of respiratory syncytial virus in paediatric patients and chronic HCV infection in both children and adults, are highlighted.
...
...